In other countries
The same active substances on other registers, the same brand first.
- ZoryveUnited States · 0.05%, 0.15%, 0.3% · cream · ArcutisSame brand
- ZoryveUnited States · 0.3% · foam · ArcutisSame brand
- DaxasBrazil · Astrazeneca do Brasil LtdaSame substance
- DaxasBrazil · Takeda Pharma Ltda.Same substance
- Daxas 250 Microgramos ComprimidosSpain · 250 µg · comprimido · Astrazeneca AbSame substance
- Daxas 500 Microgramos Comprimidos Recubiertos con PeliculaSpain · 500 µg · comprimido recubierto con película · Astrazeneca AbSame substance
- Roflumilast Aurovitas 250 Microgramos Comprimidos EfgSpain · 0,25 mg · comprimido · Aurovitas Spain, S.A.U.Same substance
- DaxasEuropean Union · AstraZeneca ABSame substance
- DalirespEuropean Union · AstraZeneca ABSame substance
- LibertekEuropean Union · AstraZeneca ABSame substance
- DaxasCroatiaSame substance
- DaxasItaly · Compressa rivestita con film · Astrazeneca ABSame substance
- Daxas 250 microgram tablettenNetherlands · Tablet · AstraZeneca ABSame substance
- Daxas 500 microgram filmomhulde tablettenNetherlands · Filmomhulde tablet · AstraZeneca ABSame substance
- Daxas®Serbia · 500mcg · film tableta · PredstavniŠTvo Astrazeneca UK Limited BeogradSame substance
- Daxas 500MCG F.C. TabletSaudi Arabia · Takeda GMBHSame substance
- ROFLAST 500 mcgSaudi Arabia · SpimacoSame substance
- DalirespUnited States · 250MCG, 500MCG · tablet · AstrazenecaSame substance
Documents
The official texts, at the regulator.
Sources and licences
Compiled by Prognia from the public register below; the register’s text is the official one.
Health Canada, Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada · Added 13 Oct 2026
Report an error or request removalCorrections from the holder or the register are welcome.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Active substance
- Roflumilast
- Strength
- 0.3 % / W/W
- Dosage form
- Foam
- Route
- Topical
- Register
- Canada (Health Canada)
- Status
- Marketed
- Authorised
- 22 Oct 2024
- Registration
- DIN 02552566
- Marketing authorisation holder
- Arcutis Canada, INC.
- ATC code
- D05AX06
- Group
- Dermatologicals
- Supply
- PRESCRIPTION